Gene · 2230
Papers1,417
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,417
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Antibody-dependent xenophagy targets viruses and bacteria for destruction. | Autophagy | 2026 | 42418235 | PubTator, text mining | PubMed |
| Copper homeostasis and cuproptosis: molecular mechanisms and therapeutic opportunities. | Mol Biomed | 2026 | 42418063 | PubTator, text mining | PubMed |
| Electric-Field-Driven Ferredoxin 1-Independent Cuproptosis Induction Overcomes Therapy-Induced Resistance in Glioblastoma. | ACS Nano | 2026 | 42411583 | PubTator, text mining | PubMed |
| Cuproptosis and prostate cancer: from molecular mechanisms and microenvironment remodeling to precision therapy. | Front Oncol | 2026 | 42388635 | PubTator, text mining | PubMed |
| Analysis of end-stage renal disease mediated by cuproptosis-related genes. | Clin Nephrol | 2026 | 42383521 | PubTator, text mining | PubMed |
| The regulatory potential of cytochrome P450-adrenodoxin interactions: Insights toward understanding redox partner regulation in drug metabolizing enzymes. | Drug Metab Dispos | 2026 | 42364571 | PubTator, text mining | PubMed |
| FDX1 Depletion Activates CD8+ T Cell Antitumor Immunity by Promoting DMBT1 Secretion in Cuproptosis of Colorectal Cancer. | Cancer Sci | 2026 | 42360182 | PubTator, text mining | PubMed |
| Epigenetic regulation of cuproptosis in cancer: mechanisms, microenvironment, and therapeutic implications. | Front Cell Dev Biol | 2026 | 42343900 | PubTator, text mining | PubMed |
| A novel mitochondrial-related gene signature for assessing the tumor immune microenvironment and predicting prognosis in human glioma. | Discov Oncol | 2026 | 42334668 | PubTator, text mining | PubMed |
| Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. | Cell | 2026 | 42330950 | PubTator, text mining | PubMed |
| Divergent roles of active-site and access-channel residues in controlling regioselectivity and catalytic efficiency in CYP154C10. | Bioorg Chem | 2026 | 42322907 | PubTator, text mining | PubMed |
| A biocompatible copper based therapeutic nanoplatform for CD44 specific tumor targeted therapy and potent immune reprogramming. | Biomaterials | 2026 | 42314235 | PubTator, text mining | PubMed |
| Cardiomyocyte programmed cell death in dilated cardiomyopathy: molecular crosstalk and therapeutic implications. | Front Cell Dev Biol | 2026 | 42311507 | PubTator, text mining | PubMed |
| Crosstalk of metabolic cell death pathways in colorectal cancer: implications for precision therapy. | Apoptosis | 2026 | 42301498 | PubTator, text mining | PubMed |
| Copper and cuproptosis-related genes as indictors for the diagnosis of injury time in traumatic brain injury: human cases and animal experiment. | Front Cell Neurosci | 2026 | 42290957 | PubTator, text mining | PubMed |
| SIRT5 mediates the pro-osteogenic effects of estrogen through FDX1 demalonylation and cuproptosis inhibition in mesenchymal stem cells. | Genes Dis | 2026 | 42290657 | PubTator, text mining | PubMed |
| Materials-Guided Gene-Ionizable Lipid Nanoparticles to Reverse Iron-Associated Immune Resistance in Renal Cancer. | Adv Sci (Weinh) | 2026 | 42261844 | PubTator, text mining | PubMed |
| Hyaluronic acid-camouflaged dendritic silica nanoparticles enable targeted cuproptosis and photothermal therapy for lung cancer. | Colloids Surf B Biointerfaces | 2026 | 42247956 | PubTator, text mining | PubMed |
| Sodium butyrate induces cuproptosis by regulating the HDAC1-SLC31A1 axis in hepatocellular carcinoma. | Food Chem Toxicol | 2026 | 42235674 | PubTator, text mining | PubMed |
| Pan-cancer analysis of the upstream regulator FDX1 in cuproptosis. | Discov Oncol | 2026 | 42230414 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2230/papers?page=3